跳至主要内容
临床试验/CTIS2022-502902-33-00
CTIS2022-502902-33-00招募中1 期

Safety and efficacy of olanzapine treatment in psychosis: Effect of genetic and epigenetic factors – covariates of treatment response - SEOTP-2022

Masarykova Univerzita0 个研究点目标入组 200 人开始时间: 2023年1月10日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • Age 18-60 years, Dg. F20 (schizophrenia) or F25 (schizoaffective disorders) according to ICD-10, Established treatment with olanzapine, or planned initiation of olanzapine treatment, Expressed the informed consent and will to co-operate, Women of childbearing potential can be included only if they are using at least an acceptable effective contraceptive measure (Chapter 8.10)

排除标准

  • Sui juris restriction or divestiture, Olanzapine or caffeine contraindication, Pregnancy, or planning to conceive, breastfeeding, Prior participation in any other trial involving investigational medication or medical devices within 14 days prior to the enrolment and during this trial, Other serious medical or psychiatric illness that is not adequately controlled and, in the investigator’s opinion, would not permit the subject to be managed according to the protocol

研究者

相似试验